Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors

Current evidence suggests sodium-glucose cotransporter 2 inhibitors (SGLT2i) do not consistently improve patient physical function, despite improvements in clinical symptoms and reductions in both adiposity and body weight. We highlight heterogenous methodologies in SGLT2i physical function trials....

Celý popis

Podrobná bibliografie

Hlavní autoři:	Cian Sutcliffe, Jack A. Sargeant, Thomas Yates, Melanie J. Davies, Luke A. Baker
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-05-01
Edice:	Frontiers in Systems Biology
Témata:	SGLT2 (sodium-glucose cotransporter 2) inhibitor Glucagon-like peptide 1 (GLP-1) receptor agonist physical function skeletal muscle glucose lowering medication mobility and ageing
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fsysb.2025.1593229/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!